Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) recently discovered a human neutralizing antibody, 10E8, that binds to the GP41 protein of HIV-1 and prevents infection by HIV-1. 10E8 potently neutralizes up to 98% of genetically diverse HIV-1 strains.By engineering the 10E8 antibody, NIAID scientists have improved the properties of 10E8 that affect manufacturability, such as solubility, while preserving its neutralizing breadth and potency.10E8 variants are useful for passive protection from infection, as therapeutics, and as a tool for vaccine development.This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404.IC: NIAIDNIH Ref. No.: E-133-2015-0Advantages: Among the most potent and broadly neutralizing human antibodies isolated to dateBroad reactivity and high affinity to most HIV-1 strainsImproved manufacturability relative to the natural 10E8 antibodyApplications: Passive protection to prevent HIV infectionPassive protection to prevent mother-to-infant HIV transmissionGene-based vectors for anti-gp41 antibody expressionTherapeutics for elimination of HIV infected cells that are actively producing virusProvider Technology ID: 3347Updated On: Nov 19, 2018Date Published: Monday, November 19, 2018Provider Classifications: Publications: Patent Application: 62/250,360PCT/US2016/06039015/772,4433003878201680077520.X16801639.220183701...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research